FTC's Proposed Rule Changes Modify HSR Reporting Requirements for Pharmaceutical Exclusive Licensing Deals

Reed Smith's Global Regulatory Enforcement Law Blog recently featured a post regarding the Federal Trade Commission's proposed changes to the premerger notification rules to clarify when the transfer of exclusive marketing, sales and manufacturing rights to a patented pharmaceutical product requires notification to the agencies under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (15 U.S.C. § 18a). The proposed rule changes are applicable only to the pharmaceutical industry. The comment period closes October 25, 2012.